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Open access unda b s t r a c t
Ethnopharmacological relevance: The ethanolic extract of Lychnophora trichocarpha Spreng. is used in
Brazilian folk medicine to treat bruise, pain and inﬂammatory diseases.
Aim of the study: The present study aimed at investigating whether ethanolic extract of L. trichocarpha,
its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by
countering hyperuricemia and inﬂammation.
Materials and methods: L. trichocarpha ethanolic extract (LTE), ethyl acetate fraction from ethanolic
extract (LTA) and isolated compounds were evaluated for urate-lowering activity and liver xanthine
oxidase (XOD) inhibition in oxonate-induced hyperuricemic mice. Anti-inﬂammatory activity in
monosodium urate crystal-induced paw oedema, an experimental model of gouty arthritis, was also
investigated.
Results: Crude ethanolic extract and its ethyl acetate fraction showed signiﬁcant urate-lowering effects.
LTE was also able to signiﬁcantly inhibit liver xantine oxidase (XOD) activity in vivo at the dose of 250 mg/
kg. Luteolin, apigenin, lupeol, lychnopholide and eremantholide C showed the anti-hyperuricemic
activities among tested compounds. Apigenin also showed XOD inhibitory activity in vivo. Luteolin,
lychnopholide, lupeol and eremantholide C, in turn, did not shown signiﬁcant inhibitory activity towards
this enzyme, indicating that this mechanism is not likely to be involved in urate-lowering effects of those
compounds. LTE, LTA, lupeol, b-sitosterol, lychnopholide, eremantholide, luteolin and apigenin were also
found to inhibit monosodium urate crystals-induced paw oedema in mice.
Conclusions: Ethanolic extract of Lychnophora trichocarpha and some of its bioactive compounds may be
promising agents for the treatment of gouty arthritis since they possesses both anti-hiperuricemic and
anti-inﬂammatory properties.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Gout is a worldwide-distributed inﬂammatory arthritis, which
is caused by the precipitation of monosodium urate crystals
(MSU) in the joints (Liote´ and Ea, 2006). Hyperuricemia is kown
to be the major risk factor for the development of gout and has
also been related to the development of cardiovascular diseases,
hypertension, nephrolithiasis and diabetes (Dalbeth and So, 2010;
Va´zquez-Mellado et al., 2004).fax: þ55 31 35 59 16 28.
gmail.com (D.A. Sau´de-
er the Elsevier OA license.In humans, uric acid forms in the ﬁnal step of purine catabolic
pathway, as a product of the oxidation xanthine by the enzyme
xanthine oxidoreductase (XDH/XOD). This enzyme exists in two
interconvertible forms: xanthine dehydrogenase (XDH) and
xanthine oxidase (XOD) (Chung et al., 1997).
The control of hyperuricemia and the treatment of inﬂamma-
tion are the major therapeutic approaches against gouty arthritis
(Liu et al., 2008). At present, allopurinol is the only drug with
clinical application in hyperuricemia that acts by inhibiting XOD
activity. Although allopurinol is effective in reducing serum urate
levels, it is not an appropriate choice to treat acute gout attacks
(Dubchak and Falasca, 2010). Moreover, this drug has been
associated with adverse effects, such as allergic reactions, skin
rashes, fever, hepatitis and nephropathy (Dubchak and Falasca,
2010; Haidari et al., 2009). Nonsteroidal anti-inﬂammatory drugs
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acute inﬂammation in gout. However, they also present some
adverse effects such as gastrointestinal toxicity, renal toxicity, or
gastrointestinal bleeding (Sabina et al., 2011). Therefore, the
search for new anti-inﬂammatory and urate-lowering drugs,
including xanthine oxidase inhibitors, which could be useful in
gouty arthritis therapy, has motivated a number of recent studies
focused on natural products (Ahmad et al., 2008; Haidari et al.,
2008, 2009; Huang et al., 2011; Liu et al., 2008; Mo et al., 2007;
Sabina et al., 2011; Zhu et al., 2004).
Species of the genus Lychnophora (Asteraceae), popularly
known as ‘‘arnicas’’, occur only in Brazilian ‘‘cerrado’’, in Minas
Gerais, Goia´s and Bahia States. Aerial parts of those species are
often used in folk medicine to treat pain, bruise, rheumatism, and
inﬂammatory diseases (Cerqueira et al., 1987; Sau´de et al., 1998).
Antinociceptive and anti-inﬂammatory activities of Lychnophora
trichocarpha ethanolic extract have been evaluated in previous
studies (Guzzo et al., 2008). This extract was also shown to inhibit
XOD activity in vitro (Ferraz-Filha et al., 2006), although the
constituents capable of inhibiting this enzyme have not been
identiﬁed. Therefore, the aim of this study was to evaluate the
in vivo anti-inﬂammatory, anti-hyperuricemic and liver XOD
inhibitory activities of L. trichocarpha and its isolated compounds
in mice.2. Material and methods
2.1. Chemicals and reagents
Xanthine, potassium oxonate, allopurinol, indometacin, luteo-
lin and apigenin were purchased from Sigma–Aldrich. Uric acid
assay kit was purchased from Bioclin (Minas Gerais, Brazil).
Monosodium urate (MSU) crystals were prepared according to
previously described method (Rasool and Varalakshmi, 2006;
Sabina et al., 2011). Sephadex LH-20 (70–100 mm) was purchased
from GE Healthcare. Silica gel 60 (40–63 mm or 63–200 mm) was
purchased from Merck. Methanol, ethanol, ethyl acetate, hexane
dimethylsulphoxide (DMSO) and Tween 80 were of analytical grade.
2.2. Plant material
Aerial parts of Lychnophora trichocarpha Spreng. were collected
in Minas Gerais, Brazil, in October, 2006. A voucher specimen
(20635) is deposited at the herbarium of Instituto de Cieˆncias
Exatas e Biolo´gicas – UFOP, Ouro Preto, Brazil.
2.3. Preparation of plant extract and fractions
Plant material was air-dried and ground. 2.2 kg of the obtained
powder was exhaustively extracted with ethanol at room tem-
perature. Solvent was removed under reduced pressure, at 40 1C,
yielding 149.0 g of dried crude ethanolic extract (LTE). Part of LTE
(130.0 g) was submitted to liquid chromatography on silica gel
(63–200 mm), using a step gradient of hexane (3.5 L), ethyl acetate
(16.0 L) and methanol (6.5 L), to yield the hexane (LTH, 0.3 g),
ethyl acetate (LTA, 53.0 g) and methanolic (LTM, 70.0 g) fractions,
respectively.
2.4. Isolation and identiﬁcation of terpenes and steroid
Part of dried LTA (20.0 g) was fractionated by columns chro-
matographic on silica gel using hexane, ethyl acetate and metha-
nol gradient as solvent. The fractions eluted with hexane: ethyl
acetate (85:15) yielded b-sitosterol (200 mg, white solid, mp
136–137 1C) and lupeol (30 mg, white solid, mp 193–196 1C).The fractions eluted with hexane: ethyl acetate (80:20) and
hexane: ethyl acetate (50:50) yielded lychnopholide (7 mg, color-
less solid, mp 128–129 1C, ethanol) and eremantholide C (500 mg,
colorless solid, mp 194–195 1C, ethyl acetate), respectively.
2.5. Isolation and identiﬁcation of ﬂavonoids
Part of dried LTA (10.0 g) was resuspended with methanol
(20 mL) and submitted to partition with hexane (830 mL) in
order to remove low polarity constituents. The methanol-soluble
fraction was chromatographed over a Sephadex LH-20 column
(1.5100 cm) eluted with methanol. Fractions 67–90 (335–
450 mL) were combined and chromatographed over silica gel,
eluted with CH2Cl2, ethyl acetate and methanol gradient. Frac-
tions 6–8, eluted with CH2Cl2: ethyl acetate (70:30), yielded
apigenin (4 mg, light yellow solid, mp4300 1C, acetone). Fractions
12–16, eluted with CH2Cl2: ethyl acetate (50:50 and 40:60), yielded
luteolin (10 mg, yellow solid, mp4 300 1C, acetone). Both com-
pounds were identiﬁed by NMR spectroscopy and by comparison
with spectral literature data (Deng et al., 2004; O¨zgen et al., 2011).
2.6. Animals
Male albino Swiss mice (25–30 g) were supplied by Universi-
dade Federal de Ouro Preto. Animals were divided into experi-
mental groups (n¼6), housed in plastic cages and maintained on
a 12-h light/12-h dark cycle. They were given standard chow and
water ad libitum. All experimental procedures were approved by
the Ethical Committee of Universidade Federal de Ouro Preto,
Brazil (no. 2010/58).
2.7. Anti-hyperuricemic effects in oxonate-induced hyperuricemic
mice and inhibition of liver XOD activity
2.7.1. Animal model of hyperuricemia in mice
An experimental animal model of hyperuricemia induced by
potassium oxonate, uricase inhibitor, has been used in order to
evaluate the anti-hyperuricemic activity of Lychnophora tricho-
carpha extract (LTE), ethyl acetate fraction (LTA) and pure com-
pounds, as described elsewhere (Haidari et al., 2008; Hall et al.,
1990; Zhu et al., 2004). Brieﬂy, potassium oxonate (250 mg/kg)
dissolved in 0.9% saline solution was administrated intraperito-
neally to each animal, except those of normal control group, 1 h
before oral administration of test compounds, once a day, for
3 days of the experiment. Mice were anesthetized with ketamine
and xylasine (100 and 20 mg/kg, respectively), 1 h after the ﬁnal
drug administration, in order to allow blood collection from
abdominal aorta. The blood was allowed to clot for approximately
1 h at room temperature and then centrifuged at 2500 g for
10 min. Sera were separated and stored at 20 1C until assay for
uric acid quantiﬁcation.2.7.2. Study design and drug administration
LTE, LTA and pure compounds were solubilized in DMSO:
Tween:water (1:1:8). Animals were divided into 13 experimental
groups (n¼6). Animals were fasted 2 h before drug administra-
tion. Mice of goups 1 and 2 (normal control and hyperuricemic
control) received only vehicle by oral route. In group 3 (positive
control), animals were treated with allopurinol (10 mg/kg body
weight, P.O.). Animals of remaining groups were orally treated
with LTE (125 and 250 mg/kg body weight), LTA (62.5 and
125 mg/kg body weight), luteolin, apigenin, eremantholide C,
lychnopholide, lupeol or b-sitosterol (25 mg/kg body weight). Treat-
ments were administrated once a day, for three consecutive days.
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Serum uric acid concentration was determined by enzymatic-
colorimetric method, using a standard diagnostic kit (Bioclin, Brazil),
according to manufacturer’s instructions.
2.7.4. Liver sample preparation
Mice livers were excised immediately after blood collection,
washed in 0.9% cold saline and rapidly stored at 80 1C until
further handling. Enzyme extraction has been performed as
described elsewhere (Haidari et al., 2008; Zhu et al., 2004). Brieﬂy,
livers were homogenized in 5 mL of 80 mM sodium phosphate
buffer (pH 7.4) and, then, the homogenate was centrifuged at
3000 g for 10 min at 4 1C. Lipid layer was carefully removed, and
supernatant was further centrifuged at 10,000 g for 60 min at
4 1C. The ﬁnal supernatant was used for enzyme assays.
2.7.5. Liver XOD activity assay
XOD activity was assayed spectrophotometrically by monitoring
uric acid formation from xanthine, according to a previously
described method (Hall et al., 1990), with modiﬁcation. The reaction
mixtures consisted of 50 mM phosphate buffer (pH 7.4), 50 mL liver
homogenate, and 1mM potassium allantoxanate, to avoid oxidation
of uric acid to allantoin, in a ﬁnal volume of 1.65mL. After
preincubation for 15min at 37 1C, the reaction was initiated by the
addition of 350 mL of 250 mM xanthine. The reaction was stopped
after 0 and 30min by adding 0.15 mL of 0.6 M HCl to the reaction
medium. Solutions were then centrifuged at 3000 g for 5 min. The
supernatant were separated and the absorbance measured at 295 nm
using a Varian 50Bio UV/VIS spectrophotometer. Protein concentra-
tion was determined spectrophotometrically by the method of
Bradford (1976) using BSA as standard. XOD activity was expressed
as nanomoles of uric acid formed per minute per milligram protein.
2.8. Effects on monosodium urate crystal-induced inﬂammation in
mice
2.8.1. Experimental model of gouty arthritis
An experimental model of gouty arthritis was used in order to
evaluate the anti-inﬂammatory activities of LTE, LTA and pure
compounds, as described previously (Rasool and Varalakshmi,
2006; Sabina et al., 2008; 2011), with modiﬁcations. Monosodium
urate (MSU) crystals were suspended in 0.9% sterile saline10 125 250 62.5 125 25 25
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Fig. 1. Anti-hyperuricemic effects of L. trichocarpha ethanolic extract (LTE), ethyl acetat
Experiments were performed as described in Section 2. Data represent mean7S.E.M. o
for statistical signiﬁcance.nPo0.05, nnPo0.01, nnnPo0.001 compared with hyperur
control group.(40 mg/mL) prior to use. Inﬂammation was induced, on the ﬁrst
day of the experiment, by intradermal injection of 0.1 mL (4 mg)
of MSU suspension into the mice right hind paw. The left paw was
injected with vehicle (negative control).
2.8.2. Study design and drug administration
L. trichocarpha extract (LTE), its ethyl acetate fraction (LTA) and
pure compounds were solubilized in DMSO: Tween:water (1:1:8).
Animals were divided into 12 groups (n¼6). Treatments were
administered 1 h before MSU injection and repeated daily for
2 more days. Mice of goup 1 were orally treated with vehicle and
served as MSU-induced control. Mice of group 2 were orally
treated with the standard non-steroidal anti-inﬂammatory drug
indometacin (3 mg/kg, P.O.). Animals of remaining groups were
orally treated with LTE (125 and 250 mg/kg), LTA (125 and
250 mg/kg), luteolin, apigenin, eremantholide C, lychnopholide,
lupeol or b-sitosterol (25 mg/kg).
Paw thickness was measured with a caliper rule (150 mm–
6 in, Vonder, China) at 0, 4, 24 and 48 h after MSU injection.
Inﬂammatory swelling was expressed as thickness variation (D).
2.9. Statistical analysis
Results of in vivo assays were presented as mean values7S.E.M.
Experimental data were analyzed using GraphPad Prism 5.0 Soft-
ware (Inc., San Diego, CA, U.S.A.). One-way analysis of variance
(ANOVA) was used, followed by Student’s Newman–Keul’s test.
P valuesr0.05 were considered statistically signiﬁcant.3. Results
3.1. Effects of LTE, LTA and pure compounds on serum urate levels
in hyperuricemic mice
Treatment with the uricase inhibitor potassium oxonate signiﬁ-
cantly increased serum urate levels compared to normal control
group. Allopurinol (10 mg/kg), as a positive control, was able to
reduce serum urate levels of hyperuricemic mice to values lower
than that found in normal animals. A three-day treatment with LTE
at the dose of 250 mg/kg, but not at 125 mg/kg, signiﬁcantly reduced
serum urate levels compared to hyperuricemic control group. Frac-
tion LTA showed signiﬁcant anti-hyperuricemic activity at doses25 25 25 25
Normal control
Hyperuricemic control
Allopurinol
LTE
LTA
Luteolin
Apigenin
Lupeol
β-Sitosterol
Eremantholide C
Licnopholide
e fraction (LTA) and pure compounds in mice pretreated with potassium oxonate.
f 6 animals. One-way ANOVA followed by Student’s Newman–Keul’s test was used
icemic control group; #Po0.05, ##Po0.01, ###Po0.001 compared to normal
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and eremantholide C were able to signiﬁcantly reduce serum urate
levels at the dose of 25 mg/kg (Fig. 1).
3.2. Effects of LTE, LTA and pure compounds on XOD activity in mice
liver
Treatment with LTE at the dose of 250 mg/kg was able to
inhibit liver XOD activity by 34.8% when compared to hyperur-
icemic control group. Apigenin also caused signiﬁcant inhibitionTable 1.
Effects of L. trichocarpha ethanolic extract (LTE), ethyl acetate fraction (LTA) and
pure compounds on xanthine oxidase activity in mouse liver in vivo.
Treatment Dose
(mg/
kg)
XOD activity
(U/mg protein)
Inhibition
(%)
Hyperuricemic
control
- 13.1671.39 –
Allopurinol 25 1.9170.12nnn 85.5
LTE 125 10.8970.72 –
250 8.5871.07nn 34.8
LTA 62,5 13.0370.73 –
125 10.2870.32 –
Luteolin 25 12.0470.37 –
Apigenin 25 8.1070.91nn 38.4
Lupeol 25 14.5470.54 –
b-Sitosterol 25 12.7070.91 –
Eremantholide C 25 12.8270.56 –
Lychnopholide 25 10.8971.07 –
Data represent mean7S.E.M. of six animals. One-way ANOVA followed by
Student’s Newman–Keul’s test was used for statistical signiﬁcance.
nn Po0.01,.
nnn Po0.001 compared to hyperuricemic control group. U¼ nanomole uric
acid per minute.
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Fig. 2. Effects of L. trichocarpha ethanolic extract (LTE), ethyl acetate fraction (LTA) and
performed as described in Section 2. Data represent mean7S.E.M. of six animals. One
signiﬁcance. nnPo0.01, nnnPo0.001 compared with with paw swelling after MSU crystof liver XOD activity at the dose of 25 mg/kg (38.4%). Allopurinol
inhibited XOD activity by 85.64% (Table 1).
3.3. Effects of LTE, LTA and pure compounds on monosodium urate
crystal-induced inﬂammation in mice
MSU crystals injection caused a signiﬁcant increase in paw
thickness when compared to negative control (left paw). Paw
swelling was found to be reduced in mice treated with LTE and
LTA both at 125 and 250 mg/kg (Fig. 2). Lupeol, b-sitosterol,
luteolin, apigenin, eremantholide C and lychnopholide, at
25 mg/kg, were also able to reduce the paw swelling induced by
MSU crystals injection. Indometacin (3 mg/kg) has also shown a
signiﬁcant anti-inﬂammatory activity in this study.4. Discussion
The sesquiterpene lactones lychnopholide and eremantholide C,
the pentacyclic triterpene lupeol and the steroid b-sitosterol have
been isolated from L. trichocarpha in previous studies (Oliveira et al.,
1996; Sau´de et al., 1998). In the present study, we have isolated
luteolin and apigenin from the active LTA fraction. As far as we
know, this is the ﬁrst report of the occurrence of these ﬂavones in L.
trichocarpha.
Anti-inﬂammatory and anti-hyperuricemic properties are con-
venient for compounds intended to treat gouty arthritis (Ahmad
et al., 2008), but none of the clinically available medicines has
both effects at the same time (Liu et al., 2008). A previous study
(Ferraz-Filha et al., 2006) demonstrated that ethyl acetate and
ethanolic extracts of L. trichocarpha inhibit XOD in vitro, showing
IC50¼6.2 and 28.8 mg/mL, respectively, which justiﬁes the study
of this species in order to identify its active compounds and to(24h)
(48h)
(4h)
(24h)
(48h)
(4h)
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pure compounds on MSU crystal-induced paw oedema in mice. Experiments were
-way ANOVA followed by Student’s Newman–Keul’s test was used for statistical
als injection in vehicle-treated mice.
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trichocarpha anti-inﬂammatory property has been demonstrated
in a preliminary screening study (Guzzo et al., 2008), as suggested
by its popular use. Thus, the present study aimed at investigating
the effects of this species and its main known constituents in an
animal model of gouty arthritis.
LTE and LTA have shown dose-dependent anti-hyperuricemic
effects on oxonate-pretreated mice in vivo. LTA seemed to be
more potent in reducing urate levels than LTE, which, a priori, was
consistent with results reported by Ferraz-Filha et al. (2006)
regarding the XOD inhibition in vitro. However, LTA was not able
to signiﬁcantly inhibit mice liver XOD activity in vivo at doses up
to 125 mg/Kg, which indicates that this fraction may accomplish its
anti-hyperuricemic effect mainly through other action mechanisms.
Lychnopholide, eremantholide C, lupeol, apigenin and luteolin
are the main responsible for LTA urate-lowering effect. Ere-
mantholide C, lychnopholide, lupeol and luteolin did not shown
signiﬁcant effect towards liver XOD activity. Thus, the urate-
lowering effects of those compounds are probably due to other
mechanisms which must be further investigated. Apigenin, in
turn, was able to moderately inhibit liver XOD activity, which was
accompanied by a reduction in serum urate levels. Apigenin has
been shown to be a potent competitive XOD inhibitor in previous
studies (Lin et al., 2002; Van-Hoorn et al., 2002), showing an IC50
value of 0.75 mM (Van-Hoorn et al., 2002). Therefore, this
mechanism is likely to contribute for the urate-lowering effects
of this compound in vivo.
MSU crystal-induced inﬂammation is characterized by inﬁltra-
tion of neutrophils and subsequent release of damage-causing
oxygen derived free radicals, lysosomal enzymes, as well as
prostaglandin E2, leukotrienes and interleukin-1 (Liu et al., 2008;
Sabina et al., 2011). Results of our study suggest that LTE and its
fraction LTA can limit MSU-induced acute inﬂammatory response.
Such activity is probably due to the combined effects of lupeol, b-
sitosterol, lychnopholide, eremantholide C, luteolin and apigenin.
Previous studies have shown that topical treatment with
lupeol or b-sitosterol inhibit neutrophil migration in 12-O-tetra-
decanoyl-phorbol acetate (TPA) induced ear oedema model
(Ferna´ndez et al., 2001; Navarro et al., 2001). Lupeol was also
shown to inhibit IL-1, TNF-a and PGE2 release by macrophages
in vitro (Ferna´ndez et al., 2001) and to modulate NF-kB transcrip-
tion factor pathway (Saleem et al., 2004). Thus, the inhibitory
effect of those compounds on MSU-induced paw oedema is
probably mediated by the above-mentioned mechanisms.
Luteolin and apigenin have been found to modulate COX-2
and iNOS expression and to down regulate the release of NO and
TNF-a (Kim et al., 2004; Lo´pez-La´zaro, 2009; Mattace Raso et al.,
2001). Apigenin was shown to inhibit NF-kB expression as well
(Kim et al., 2004). Moreover, these ﬂavones are known to possess
strong antioxidant and free radical scavenging properties (Gomes
et al., 2008), and could thus reduce cellular damage caused by
superoxide and other reactive oxygen species that are involved in
acute inﬂammation in gout.
Although some sesquiterpene lactones structurally related to
lychnopholide and eremantholide C have been shown to inhibit
the DNA binding of NF-kB (Ru¨ngeler et al., 1999), the exact action
mechanism by which these two compounds exert their anti-
inﬂammatory activity has not been well elucidated so far.5. Conclusion
The ethanolic extract of L. trichocarpha (LTE) and its ethyl acetate
fraction (LTA) were able to reduce serum urate levels in hyperur-
icemic mice. Anti-hyperuricemic activities of LTA and LTE are, in
part, due to the synergistic actions of the apigenin, luteolin, lupeol,lychnopholide and eremantholide C. The anti-hyperuricemic activ-
ity of the apigenin seems to be mediated by XOD inhibition, while
eremantholide C, lupeol, luteolin and lychnopholide are likely to
possess other action mechanisms. Furthermore, LTE, LTA and its
pure constituents proved to be effective in reducing MSU-induced
paw oedema in mice. Therefore, L. trichocarpha and some of its
active compounds may be promising agents for the treatment of
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